Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic HIV vaccines.

Bruce L Gilliam1, Robert R Redfield

  • 1Institute of Human Virology, University of Maryland, 725 West Lombard Street, Baltimore, MD 21201, USA.

Current Topics in Medicinal Chemistry
|October 8, 2003
PubMed
Summary

Antiretroviral therapy has reduced AIDS deaths but faces challenges like resistance and limited access. Therapeutic vaccines offer a potential long-term HIV-1 viral control strategy, especially for global access.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term graft and patient survival following endovascular intervention for renal artery stenosis in transplanted kidneys: a single-center experience.

Annals of vascular surgery·2026
Same author

Patient-reported Opioid use and Pain Management After Living Kidney Donation.

Transplantation direct·2026
Same author

Transplant center practices that maximize access to living kidney transplantation: the Penn experience.

Frontiers in immunology·2026
Same author

Rituximab-based antibody mediated rejection therapy modestly reduces Xenoreactive antibodies: Implications for pig-to-human xenotransplantation.

Transplant immunology·2025
Same author

Donor-recipient age mismatch and outcomes in liver transplantation: A scientific registry of transplant recipients database analysis.

World journal of transplantation·2025
Same author

Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID.

Viruses·2025

Area of Science:

  • Immunology
  • Virology
  • Infectious Diseases

Background:

  • Antiretroviral therapy (ART) has decreased AIDS-related mortality in developed nations.
  • ART presents challenges including lifelong adherence, toxicity, resistance, and limited global access (only 1 in 20 infected).
  • Current HIV-1 treatment strategies require reevaluation, especially for resource-limited settings.

Purpose of the Study:

  • To review the scientific rationale for therapeutic HIV-1 vaccines.
  • To discuss various therapeutic vaccine candidates evaluated to date.
  • To explore the potential of therapeutic vaccines for long-term viral control and global HIV-1 treatment.

Main Methods:

  • Review of scientific literature on therapeutic HIV-1 vaccines.
  • Evaluation of diverse vaccine platforms including recombinant glycoproteins, inactivated virus, regulatory proteins (Tat), cytokines (IFN-α), DNA vaccines, and viral vectors.
  • Analysis of immunomodulatory approaches for HIV-1 management.

Main Results:

  • Therapeutic vaccines aim for long-term viral control rather than eradication.
  • Various vaccine types have been explored, showing potential for immunomodulation.
  • Successful therapeutic vaccines could be inexpensive and globally exportable.

Conclusions:

  • Therapeutic vaccines represent a promising strategy for long-term HIV-1 management.
  • This approach may offer new insights into HIV-1 pathogenesis and host-virus interactions.
  • Therapeutic vaccines hold potential for affordable and accessible HIV-1 treatment worldwide.

Related Experiment Videos